Cargando…

Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy

BACKGROUND: Hypoglycemia poses a significant clinical and economic burden to patients with type 2 diabetes mellitus (T2DM). Minimizing the risk of hypoglycemia is an important component when managing patients with T2DM. Understanding hypoglycemia rates and the associated economic consequences can he...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raju, Aditya, Shetty, Sharash, Cai, Beilei, D’Souza, Anna O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398174/ https://www.ncbi.nlm.nih.gov/pubmed/27123911 http://dx.doi.org/10.18553/jmcp.2016.22.5.483

Ejemplares similares

Association Between Metformin and Sulfonylurea Monotherapies and Cancer Incidence: A Real-World Cohort Study in Shanghai, China
por: Ye, Jing-Hong, et al.
Publicado: (2019)

Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin?
por: Muthukrishnan, J., et al.
Publicado: (2012)

Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis
por: Raju, Aditya, et al.
Publicado: (2021)

Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study
por: Roumie, Christianne L., et al.
Publicado: (2017)

Role of Octreotide in Sulfonylurea-Induced Hypoglycemia
por: Zafar, Sheema, et al.
Publicado: (2021)

Sulfonylurea-Induced Hypoglycemia in a Patient With Cirrhosis
por: Braet, Corey, et al.
Publicado: (2020)

Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia: A nested case-control analysis
por: Bodmer, Michael, et al.
Publicado: (2008)

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Gordon, Jason, et al.
Publicado: (2016)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas
por: Mamtani, Ronac, et al.
Publicado: (2014)

Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review
por: Mohan, Viswanathan, et al.
Publicado: (2022)

Initial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptin
por: Freeman, Jeffrey S
Publicado: (2013)

A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy
por: Gitt, Anselm K, et al.
Publicado: (2015)

Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis
por: Mekuria, Abraham Nigussie, et al.
Publicado: (2019)

Spectrophotometric Methods for the Determination of Linagliptin in Binary Mixture with Metformin Hydrochloride and Simultaneous Determination of Linagliptin and Metformin Hydrochloride using High Performance Liquid Chromatography
por: El-Bagary, Ramzia I., et al.
Publicado: (2013)

Starting with low dose sulfonylurea and metformin in early stage type 2 diabetes mellitus
por: George, Joe
Publicado: (2015)

SAT-LB110 Sulfonylurea-Induced Hypoglycemia: To Use Octreotide or Not
por: Romeu, Jose, et al.
Publicado: (2020)

Pharmacogenetics of Hypoglycemia Associated with Sulfonylurea Therapy in Usual Clinical Care
por: Mitchell, Sabrina L, et al.
Publicado: (2020)

A Case of Hypoglycemia With Concomitant Use of a Sulfonylurea and Clopidogrel
por: Ruiz, Brent, et al.
Publicado: (2022)

Analytical Enantio-Separation of Linagliptin in Linagliptin and Metformin HCl Dosage Forms by Applying Two-Level Factorial Design
por: Jadhav, Sushant B., et al.
Publicado: (2016)

The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus
por: Mita, Tomoya, et al.
Publicado: (2018)

Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients
por: Susilawati, Elis, et al.
Publicado: (2023)

Combination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes
por: Haak, Thomas
Publicado: (2015)

Linagliptin/metformin/pembrolizumab interaction: Various toxicities: case report
Publicado: (2022)

Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
por: Kwon, Christina S., et al.
Publicado: (2018)

Predictors of metformin monotherapy failure in gestational diabetes mellitus
por: Benido Silva, Vânia, et al.
Publicado: (2022)

The effectiveness of octreotide at different doses for sulfonylurea-induced hypoglycemia following overdose
por: Gul, M, et al.
Publicado: (2007)

Stress Cardiomyopathy Induced by Refractory Hypoglycemia Due to Acute Sulfonylurea Intoxication
por: Shah, Binoy K, et al.
Publicado: (2023)

Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV
por: Strojek, Krzysztof, et al.
Publicado: (2021)

Cost‐effectiveness of second‐line empagliflozin versus liraglutide for type 2 diabetes in the United States
por: Reifsnider, Odette S., et al.
Publicado: (2022)

Reactive Hypoglycemia From Metformin Immediate-Release Monotherapy Resolved by a Switch to Metformin Extended-Release: Conceptualizing Their Concentration-Time Curves
por: Akram, Ayesha
Publicado: (2021)

Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis
por: Qian, Dan, et al.
Publicado: (2018)

Cost‐effectiveness analysis of empagliflozin versus sitagliptin as second‐line therapy for treatment in patients with type 2 diabetes in the United States
por: Reifsnider, Odette, et al.
Publicado: (2020)

Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study
por: Roberto, Giuseppe, et al.
Publicado: (2022)

Low Branched Chain Amino Acids and Tyrosine in Thai Patients with Type 2 Diabetes Mellitus Treated with Metformin and Metformin-Sulfonylurea Combination Therapies
por: Sriboonvorakul, Natthida, et al.
Publicado: (2021)

Linagliptin monotherapy compared with voglibose monotherapy in patients with type 2 diabetes undergoing hemodialysis: a 12-week randomized trial
por: Mori, Katsuhito, et al.
Publicado: (2016)

Experience with enteral sulfonylurea monotherapy for extremely low birth weight infants with hyperglycemia
por: Nakagawa, Ai, et al.
Publicado: (2022)

Deintensification of Treatment With Sulfonylurea and Insulin After Severe Hypoglycemia Among Older Adults With Diabetes
por: Alexopoulos, Anastasia-Stefania, et al.
Publicado: (2021)

Discordant Timing of Hypoglycemic Agent Screening Causing Delayed Diagnosis of Sulfonylurea-Induced Hypoglycemia
por: Folick, Andrew, et al.
Publicado: (2022)

SAT156 Two Cases Of Hypoglycemia From Inhalation Of Heroin Adulterated With A Sulfonylurea
por: Kim, Keun Young, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9s4ivkkfqa7r1ece99nfkm5if7